- NewsCategory：
- All Company news Industry news
common83One result
-
1031
Gotham Therapeutics Establishe≠★α§s Advanced Oncology Profiling Cascade with ProQin×>∞¥ase to Progress its Portfolio> of Epitranscriptomic Drug Candαλidates
Gotham Therapeutics Establiσ✘shes Advanced Oncologyλ≥ Profiling Cascade with ProQinase to Pr>₽♦∏ogress its Portfolio of Epπ₩β&itranscriptomic Drug CandσidatesWEDNESDAY, OCTOBE∑♥R 30, 2019Gotham Therapeutics, a bio₹↔₽♣technology company developing a novel'σ drug class targeting♣☆₹∑ RNA-modifying proteins, and ÷&↑ProQinase, an early stage drug-discovery comp∑λany, recently acquired by Ω&ε"Malvern/PA-based Reaction Biology Co♦π→£rp., today announced that they have established a♦★n array of advanced biochemical and cell¥Ω>ular assays to characterize epitranscriptomic-d≤ ε©irected compounds.“Establishing tailored target e♦'®→ngagement, cell biology, phenotypic, and i≠">n-vivo assays to eva§♠luate compounds originating from our ☆☆ ÷three most advanced epiΩ♣αδtranscriptomic programs in parallel is a crucial®≈ next step to develop our broad pipel×φine towards the clinic∞£,” said Dr. Gerhard Müller, Ch→♠€ief Scientific Officer of Gotham The$€π∏rapeutics. “By pursuing the ↑✔☆full range of the reader₩✔-writer-eraser continuum, we are able to foc₹∑÷us on targets with the most compelling liΩε₩nks to disease and advance those progra☆®↕ms in tandem.”“Combining our h→§Ω↑igh proficiency in providing customized s★olutions as early stage drug-discovery se♥¶↔±rvices, including tailor-made biochemical and≠δ> cell-based assays, w←↔←ith Gotham’s expertise in epitran₩☆βscriptomics, we were able to establish •∑ in a very short time a set of cust&•omized enzymatic and cellular assays for compou↓•nds addressing three$α different mRNA-modifyiπ'±¥ng targets,” said Dr. Sebastian Dempe, ±<Chief Executive Officer of ProQina¶§se. “We look forward to supporting Gotham as th∑"λe company advances its programs into ♠←≠lead optimization and to cont♥₹∑inued work with the Gotham team assistε×ing the company to advance its br↓ oad pipeline in a time-efλ÷fective manner.”In addition to establishing<δ¶↔ a tailor-made profiling cascade for cλ≤®↕ompounds from its th←§ree most advanced programs, Gotham ☆¶×has also made progress in strengthening its d₩α÷✔rug discovery engine and developing its candida© €↑te base. Gotham previously completβ'σed the gene-to-lead phase for its drug di←φδscovery project targeting the METTL3/ME₩☆"'TTL14 complex and established a robust d€↑&☆iscovery process as a platform for future p"απrojects. The company has also generated ↕a library of high-quality compounds tailor-∑£made for accelerated hit generation and hit-t₽φ ≠o-lead expansion against large parts of the e γpitranscriptomic target space. This library incl♠✔udes a collection of over 2,000 analogues c£&&overing over 80 distinct chemotyp♣↓<™es that will be used to further accelerate Goth÷§≠✘am’s drug discovery efforts as it expands∑ its pipeline.The ori§¶ginal link:https://www.pharmafocusasia.com/news✘®↑/gotham-therapeutics-establishes-advanced-onco¥☆εlogy-profiling-cascad÷★e-with-proqinase-to-progrβ$≤ess-its-portfolio-of-epitranscrγΩ iptomic-drug-candidates2019 Asi∑¶✘a-pacific pharma IP Leader Summit: http://en.&₽zenseegroup.com/p/510934/will be held in&nb≠>™®sp;Beijing on November 14-15,®↔γ and will attract more&Ω than 500 industry experts fro→ε<πm domestic and foreig₽≠¶λn pharmaceutical compan✘ πies, biotechnology companies, gov±≠ ernments, associations, law <•firms, intellectual property agents and ot≠₩her companies to attend.Official reg♣©istration and consultation♥→γ channels:Contact：Ann∞♥Phone: 021-65650305Email：Mark♠ ≠♠eting@zenseegroup.comhttp://en.zenseegr∏₹®≤oup.com/p/510934 -
1030
Gilead and Glympse Bio Announce Strate€☆gic Collaboration for Use σ↓λof Biomarker Technology in NASH Clinical Develop≠✘ment
Gilead and Glympse Bio Announce Sγ₽trategic Collaboration for Use of Biomarker Tech ≤nology in NASH Clinic↑→♣al DevelopmentTUESDAY, OCTOBER 29, 2019Gilead S∑♦>♦ciences Inc. and Glympse Bio, Inc., today announcᧀed that the companies have☆ entered into a strategic collab↔¶★oration in nonalcoholic steatohepatitis (NASH)♣λσ∞ clinical development. Glympse Bio’s propε₹rietary synthetic biomarkers – bioeng✘ineered to identify stage and progression of♥ disease as well as early detectio δ&₩n of treatment response – ¥♠©≥will be used to determine clinical trial partiα'♥cipants’ stage of disease at initial screening•≠∏ and to determine responses to study treεε"atment in Gilead’s NASH clinical program.“We≠ are excited about the opportunity t↔&↑o partner with Glympse Bi₩→β£o to help inform our NASH developδ≈©×ment program,” said Mani ☆×πγSubramanian, MD, PhD Senio∏€r Vice President, Liver Di™&$seases, Gilead Sciences. “By util♥₽σαizing this innovative technology☆₹∞ε, we hope to better characterize this complex ♦↔disease and improve our und→↑®∞erstanding of how our compounds impact disβ±α"ease progression.”Glympse Bio’s proprietary tδ≠α"echnology, Glympse Inside™, combines synthetic biε©δomarkers with machine learning approaches t&"o identify the stage and mo€•←↔nitor progression of important, complex diseases ≤₹ ★such as cancer, fibrosi↕₹s, inflammation, and★ ↑ infections, in real tφ™ime.“We are very excited ¶₩✔Ωabout partnering with Gilead, a leader in drug d↕≈εevelopment, to help dri÷ δve earlier and more favorable outcomes for $φ'↔patients,” said Caroline J Loew, Pre✘γ₩sident and CEO, Glympse Bio±•✔≠. “Gilead’s commitmenεπ∑t to developing innovative medicines in ₹± areas of high unmet medical need aligns ≠★αwith our mission of transforming ©ε♦>disease detection and measuring treδ≈™atment response, all with the goaγ€★l of helping improve the lives of pati"±♣ents.”information sourε←ce:pharma focus AsiaThe original link:httφ≈ps:https:https://www.pharmafocusasia.c≠≥om/news/gilead-and-glympse-bio-'®≈announce-strategic-c±>"≤ollaboration-for-use-o↑•₹f-biomarker-technolo>Ωgy-in-nash-clinical-development201ε♦₹9 Asia-pacific pharma IP Lead≈er Summit:http://en.zenseegroup.com/p/510934/&♥ £↓nbsp;will be held in B®±¶&eijing on November 14-15, and wπαill attract more than "×500 industry experts from domestic ↑ ✘ and foreign pharmac®®eutical companies, biotechnology compani☆ε¶es, governments, associations, law firms, intellectual property agents and ∞ other companies to attend.Official re∑₽♣gistration and consultation channels:Contact：AnnP♠↓¥♣hone: 021-65650305Email：Marketing@☆↕&zenseegroup.comhttp://en.zenseegroup.com/p'§</510934 -
1029
HistoIndex Announces Global Partnerships To$₩ Expand AI-Based Digital Pathology Pla♥$∏¥tform
HistoIndex Announces Global Partnerships To ₩✔♦Expand AI-Based Digital Paδ¥π✔thology PlatformMONDAY, OC≥✔¶TOBER 28, 2019HistoIndex ₩λ↕announces the expansion of its AI-↕γ≤based digital pathology platform to₽♥wards large-scale NASH p∑✔reclinical programs for p§ harmaceutical and biotec Ω×♥h companies to achieve quantifiable and γ✔reproducible data on therapeutic responseλ✘ ∑s in NASH animal models,♣β and to aid CROs as well↕☆€ as research agencies in validaπ↑↓ting new models mimicking the <♦NASH disease.Published preclinical stσ"≈udies have demonstraε↔€ted the use of HistoIndex's fully quant✔ifiable Second Harmo✔£±'nic Generation (SHG) technology as a hi≥ghly accurate stain-fr✔×ee method that can mon•γπitor the efficacy of various therapeu♦€tic agents, by quantifying more t≠β<←han 450 NASH-associated parameters in f₩☆ibrosis, inflammation, ballooning and s÷•←★teatosis. The information of these NASH$♥-associated parameters ga ↕thered from the entire l☆₹iver tissue, provides comprehensive ins<₽ights on the mechanism of action of thβ∏♠'e therapeutic agent. As a drug dis✘★♠σcovery tool, HistoIndex's♦§ SHG-enabled digital pathology platform will a®↔>llow pharmaceutical and biot>✘ech companies to select promisingλγ↓→ lead candidates for further optimi✔€αzation and make informed decisio₩'ns in the management of th≤'§eir NASH drug development pipeline.In additᶥion to ongoing NASH clinical t↑•rials, HistoIndex is current• §©ly involved in multiple p ↓reclinical studies, most o∞ αf which are conducted &¥ by major pharmaceutical and biotech companies, σ♠medical universities, CROs a≠nd research agencies. No↑↕"tably, HistoIndex has recently entered into₩ a collaboration with the A*STAR's Genome Institu★•te of Singapore (GIS) to validate their in vi±≤♠×vo and in vitro NASH models based β®on Asian-centric clinical data. Says Pr¥₹£♠ofessor Patrick Tan, Execu§π☆≤tive Director of the Genome Institute of∏≠ Singapore (GIS), "At GIS, we con↑₹ duct our preclinical studies on fatty liver invδ↔♠olving data from animal models based on patie¥∑<nt-derived transcriptomic data. This has a high ₽♦✔translational potential as it helps us to✔÷" pinpoint new therapeutic® € targets and their validation.×♦&↔ Therefore, using a fully quanβ₹∏αtitative, reliable and objectiveλ÷ pathological evaluation such as Hist♣© ©oIndex's AI-based digital pathology platf>∏•$orm is essential to t¥≤¥γhe success of our efforts in therap✘∏&eutic target discovery."Hist≥oIndex is also a partner with globβ×ally-renowned CRO, WuXi Apptec,β£ in advancing their NASH prec ♠linical programs with advan↕♣ced R&D and smart imaging an<φδalysis capabilities. £↕Published study data will be availab∑♦le for discussions during networking opport<βσunities throughout AASLD's€§λ The Liver Meeting® i←< n November 2019. →"We are very excited to extend our AI>α≥×-based SHG platform toδφ♣ preclinical studies to ≥→ help companies with drug d&"↑iscovery programs select pro♥≈§<mising lead candidates for further optimizati★on and subsequent clin₹ Ωical development," says Dr Poon Thong Yuen, Chiefε Executive Officer of HistoIndex. "O₩♠© ur SHG image analysis plat←★∑form has already been used to analyze the ef§♦ficacy of a series of promisi" ng drug candidates for NASH wit ®Ωhin various animal models commonly-uε&¥εsed by the industry, and w¶ e believe these preclinical partne✔δ✘rships will help drive the a≥¥€doption of our platform significa ₹✔εntly."information source:pharma focus Asia★¥¥✔The original link:https:https://www. ± pharmafocusasia.com/news↔£↔♥/histoindex-announces-global-partnershi×¥•ps-to-expand-ai-based-digital-pathology-platfor★♣δm2019 Asia-pacific pharma IP Leader"∞ Summit: http://en.zenseegroup.com/p/5&₹10934/will be held in §λ€₹Beijing on November 14-1α₹±↔5, and will attract more than 500 industry expertΩ∞>±s from domestic and foreign phar★××₹maceutical companies, b§iotechnology companies, governments, associati↔σ₹ons, law firms, intellectual property agents and '≤∞other companies to atte≠"ε≤nd.Official registration and consult∞¥ation channels:Contact：An∏>∏∑nPhone: 021-65650305Email：Marketi×ε↔$ng@zenseegroup.comhttp:♥©β//en.zenseegroup.com/p/510934 -
1028
AVROBIO Receives Orphan-Drug D>≠€÷esignation from the U.S. FD↔☆φ>A for AVR‑RD‑02 for the Treatment ♠✘<→of Gaucher Disease
AVROBIO Receives Orphan-Drug Designation fro→→δm the U.S. FDA for AVR‑RD‑02 for the Treatmentφ☆©↔ of Gaucher DiseaseFRIDAY, OCTOBER 25, 2019Aε∑&₽VROBIO, Inc., today announced that the U.S. Foodβ® and Drug Administration (FDA™≥♠) has granted orphan-drug designation →''for the Company’s inve≠×βstigational gene therapy←≤, AVR-RD-02, for the treatment of Gaucε&™her disease. AVR-RD-02 consists of the patient☆✘’s own hematopoietic stem cells, ge☆★§≈netically modified to express glucocerebrosidas©πe (GCase), the enzyme that is deficient in Gauche$<←r disease. The Company is actively recrui®ting in Canada for its Phas≈ ≠e 1/2 clinical trial of AVR-RD-02, which seeks t™₽>¥o evaluate the safety and efficacy of the thera'™py in patients with Type ♦ 1 Gaucher disease.“Under the exist"≠ing standard of care, patient&<δs with Gaucher disease are bound♥π to a lifelong infusion schedule of en±zyme replacement therapies, and still exp≥©¥erience painful and progressive symptoms★' such as debilitating musculoskeletal pain and≥₩ fatigue,” said Birgitte Volck, MD, P •hD, President of Research≠♠' and Development at AVROBIO. “Orphan-drugδ₹ designation recognizeσφβ÷s the unmet need of populations with₽✘₹ rare diseases like Gaucher where AVROBIO÷βπ strives to transform lives by addressing the✔✘↕ underlying cause of the disease wit®h a single dose of ge←<ne therapy.”Orphan-drug designation is&≥♥∑ granted by the FDA to drugs andβ' biologics which are intended for the safe a•¶φ÷nd effective treatment, diagnosis or preveε§ntion of rare diseases or §✔α✘conditions that affect feβ÷₽₩wer than 200,000 people in the United States.αβ Orphan-drug designation provides certain ince¶₩πntives, which may include t"σ>₩ax credits towards the cos≈✘₩t of clinical trials and prescrip✔≥™φtion drug user fee wai↑€vers.information source:pharma foc&ε✘us AsiaThe original link✔↕→γ:https:https://www.pharmafocusas¥σ✔ia.com/news/avrobio-receives-orphan-drug-desi∞'♣≤gnation-from-the-us-∏₩¶fda-for-avrrd02-for-the-treatment-of-₽δgaucher-disease2019 Asia-pacific pharma IP♥§→ Leader Summit: http://en.zenseegroup.com/p/≤'510934/will be held in Beijing εβ;on November 14-15, and wil $♣l attract more than 500 ind© ustry experts from domes↑ ≈tic and foreign pharmaceutical companies, biotechφnology companies, governments, associations, ♠≥ law firms, intellectu÷•al property agents and other ↓companies to attend.Offic♥ial registration and c§↓onsultation channels:Conta♦ •"ct：AnnPhone: 021-656βλ50305Email：Marketing@zenseegroup.comhttp://en.zeγ÷π♥nseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neuroi"♥σnflammation-Targeted Pipe<×♦★line Through Acquisition of Smith Therapeuα¥tics
FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a ♦✘biopharmaceutical company developin¥×g therapeutics to extend brain healt☆αh, today announced the acqu§•≈εisition of Smith Theα•rapeutics, a private>∑ biopharmaceutical comp<σ ₹any with a shared goal of targeting neuroiε§&§nflammation to treat ne→±urodegenerative disease. Smith Th"$ ♦erapeutics’ Founder and Chief Executive Of←♠€ficer Philip Ashton-Rickardt, Ph.D.,<♥ has joined the senior leadership team at↔ ↑ AZTherapies as Senior Vice Preside©≥♣nt of Immunology. Financial &¶terms of the acquisition were β∞not disclosed.Smith Therapeutics’ propriet™γary research platform focuses "±on the use of modified T c" ells to restore a healthy balance of inflam¶$↓×matory and regulatory ☆✘π≤cells in the brain. To date, Sεδ± mith has successfully engine&✘ered immunosuppressive T regulatory (Treg) ceδ$'lls with Chimeric Antigen Receptors €π(CARs) targeting brain glial cells≈÷φΩ. Previous research has demonstrated the ↓∑ability of Tregs to dampen mic€→£±roglial activity and reduce neu&♥roinflammation in mo ✘÷dels of neurodegeneration, su★™♦₽ggesting their potential utility in the treat&>→ment of diseases including Progr☆∑essive Supranuclear Palsy (PSP), Alz♠×heimer’s disease, Parkinson’s diseas≤♣₹e, Huntington’s disease, Amyotrophic Lateral S"¥λclerosis (ALS), and ←&≈others.“This acquisitio'↔§≠n represents a meaningful ste∑δp forward for us as ₹±we continue to strengthen our lea≥γ¥>dership position in the development of thera≥ ¶pies targeting neuroinflammation to stop or > slow the progression₽×δ of neurodegenerative diseases,” said David R. El$"maleh, Ph.D., Founder, ₹→CEO, and Chairman of AZTherapies. “We are exci✔↑☆ted to be working with Philip as we add this σ♥cutting-edge technology to our portfolioφ of innovative programs. An estα®™≥eemed immunologist and inventor of the teπ♥chnology, Philip brings unparalleled expertise to♠± the company and we look forward to advancing t₩★£his CAR-Treg program further into IND-e¶nabling studies and into clini ≥$cal development as rapidly as possible.”D≈§r. Ashton-Rickardt commented on the acquisitio£&n and his appointment:☆↔φ★ “Our shared rationale of targeting neu★ roinflammation as the root caus"'☆¥e of neurodegenerative disease makα≥φεes this acquisition a great strategic fit for us.↔≈ With AZTherapies’ expertise in drug developmπ₹ent and clinical trial ★∞∞♦execution, we believe that together, we ₹≤>±are well positioned to advance∞ ↑ our CAR-Treg technology™→φ and fundamentally change✘± neurodegenerative disease progression.”Prior to ↓λ>launching Smith Therape'§≥utics in 2017, Dr. Ashton-Rickaλ♠$rdt was Chair in Imm€↑↓®unology at Imperial College↔>§ London, Visiting Professor'γ , Brigham and Women’s Hospital, Harvard α≠βMedical School, and Associate Professor i€≈∞≠n the Department of Paσλthology at the University of Chicago. His workπ has been recognized by his pee ε✘©rs through the award ♦♥of tenure from The University of Chic&₽αago and by his fellow citizens as a recipie÷∏nt of the Early Career Award ♦§®↑for Scientists and Enginφeers from President Bi¥ll Clinton. He has publishedλπ₹ more than 65 peer-reviewed papers in mo&£☆re than 30 academic journals (including Ce↕π™ll, Science, Immunity, and Nature Immunology), haγα≈∏s served as an editor for several academic journa↔ ls, and has been a member of grant review boardsγα globally. Dr. Ashton-Rickardt receβ"<ived a B.Sc. in Biochemistry' from the University of London, King’s College λ↑ £with honors, a Ph.D. in ββMolecular Biology from the Univers≠εεity of Edinburgh, and comple®∑ted post-doctoral work at the Un$iversity of Edinburgh and the Massachus™δ→etts Institute of Technology in Molecular B♥≤↓πiology and Molecular Immunology, respective¥✘©ly.information source:pharma ∑× ¶focus AsiaThe original lγ♣✘ink:https:https://www.pharmafocusasia.comγ₹≤/news/aztherapies-strengthens-neuroinflammation-t ₽Ω♠argeted-pipeline-through-acquisition-of-smith-♥↕therapeutics2019 Asia-pacific pharma IP ♥♠±σLeader Summit: http://en.zenseegro£δσ±up.com/p/510934/will be helπ$>✘d in Beijing &'₩; on November 14-15, '↔and will attract more than 500 industry↕§÷ experts from domestic and foreign€λ≤' pharmaceutical companies, £↑α≥biotechnology companies, government←≥s, associations, law firms, intellectual proper •↕∏ty agents and other companies to atte∑¥δλnd.Official registration and"↔• consultation channels:Contact：AnnPhone: 02φ♥ 1-65650305Email：Marketing@zens∞βδeegroup.comhttp://en.zenseegroup.com/∞φ'®p/510934
Contact Us
Zensee_Daystar online
© 2011-2016